Different Proarrhythmic Effects of Aconitine on Healthy and Long QT Syndrome Patients with Human Pluripotent Stem Cell-Derived Cardiomyocytes

A B S T R A C T

Aconitine is the main toxic component in aconite, a traditional Chinese medicine, which was widely used in emergency medicine. Aconitine is highly toxic, and a single dose of 0.2mg can cause malignant arrhythmias\death in adults. Early studies have shown that aconitine can improve arrhythmia in patients by affecting the calcium channel. The dual nature of aconitine therapy and toxicity is puzzling. While cardiac Ca2+ channel opening during repolarization has long been documented in normal human cardiac myocytes, the cellular effects and mechanism of ACO in Long QT syndrome patient remains unexplored. This study aimed to assess the proarrhythmic effects of ACO in healthy and Long QT syndrome patients with human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). ACO concentration-dependently (0.05 ~ 5.0 μM) decreased amplitude, which has no significant effect on cell index of normal hiPSC-CMs. While ACO 5.0 μM decreased cell index between 5-30min for Long QT syndrome hiPSC-CMs. Meanwhile, ACO had no significant effect on the amplitude and frequency of calcium transients in normal cardiomyocytes, but it significantly increased the frequency of calcium transients in special cardiomyocytes of LQT disease at 5 μM. Meanwhile, 0.05- 5 μM ACO significantly shortened the action potential duration of human cardiomyocytes in both normal and LQT groups. Effect of ACO on L-type calcium current was detected in both normal hiPSC-CMs and LQTs hiPSC-CMs; it showed a similar blockage, which suggested that L-type calcium current may not be the major target on the effect of ACO on LQT disease. In conclusion, our data suggest that ACO had different effect on human cardiomyocytes in normal and LQT (hiPSC-CMs).

Keywords

Long QT syndrome, aconitine, hiPSC-CMs



Get access to the full version of this article.

Article Info

Article Type
Research Article
Publication history
Received: Thu 12, Aug 2021
Accepted: Sat 28, Aug 2021
Published: Tue 14, Sep 2021
Copyright
© 2023 Yue Gao. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.JSO.2021.02.03

Author Info

Yang Liang Xieguanghui Wang Zihan Huangguangyao Zheng Bin Zhu Jin Miao Hong Qian Yue Gao

Corresponding Author
Yue Gao
Beijing Institution of Radiation Medicine, Beijing, China

Figures & Tables



Get access to the full version of this article.

References

1.     Jeon SY, Jeong W, Park JS, You Y, Ahn HJ et al. (2020) Clinical relationship between blood concentration and clinical symptoms in aconitine intoxication. Am J Emerg Med 40: 184-187. [Crossref]

2.     Xie D, Wu J, Wu Q, Zhang X, Zhou D et al. (2021) Integrating proteomic, lipidomic and metabolomic data to construct a global metabolic network of lethal ventricular tachyarrhythmias (LVTA) induced by aconitine. J Proteomics 232: 104043. [Crossref]

3.     Zhi M, Liu K, Han S, Xu J, Li W et al. (2020) Influence of Different Dosage Forms on Pharmacokinetics of 6 Alkaloids in Raw Aconiti Kusnezoffii Radix (Caowu) and Chebulae Fructus- (Hezi-) Processed Caowuby UPLC-MS/MS. Biomed Res Int 2020: 1942849. [Crossref]

4.     Fatica EM, DeLeonibus GA, House A, Kodger JV, Pearce RW et al. (2019) Barth Syndrome: Exploring Cardiac Metabolism with Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Metabolites 9: 306. [Crossref]

5.     Guo X, Gu X, Hareshwaree S, Rong X, Li L et al. (2019) Induced pluripotent stem cell-conditional medium inhibits H9C2 cardiomyocytes apoptosis via autophagy flux and Wnt/β-catenin pathway. J Cell Mol Med 23: 4358-4374. [Crossref]

6.     Pan Z, Ebert A, Liang P (2020) Human-induced pluripotent stem cells as models for rare cardiovascular diseases: from evidence-based medicine to precision medicine. Pflugers Arch 473: 1151-1165. [Crossref]

7.     Sugrue A, van Zyl M, Enger N, Mancl K, Eidem BW et al. (2020) Echocardiography-Guided Risk Stratification for Long QT Syndrome. J Am Coll Cardiol 76: 2834-2843. [Crossref]

8.     Matsuda S, Ohnuki Y, Okami M, Ochiai E, Yamada S et al. (2020) Jervell and Lange-Nielsen syndrome with novel KCNQ1 and additional gene mutations. Hum Genome Var 7: 34. [Crossref]

9.     Kim TY, Jeng P, Hwang J, Pfeiffer Z, Patel D et al. (2019) Short-Long Heart Rate Variation Increases Dispersion of Action Potential Duration in Long QT Type 2 Transgenic Rabbit Model. Sci Rep 9: 14849. [Crossref]

10.  Obergrussberger A, Juhasz K, Thomas U, Stölzle Feix S, Becker N et al. (2016) Safety pharmacology studies using EFP and impedance. J Pharmacol Toxicol Methods 81: 223-232. [Crossref]

11.  Wu J, Wang X, Chung YY, Koh CH, Liu Z et al. (2017) L-Type Calcium Channel Inhibition Contributes to the Proarrhythmic Effects of Aconitine in Human Cardiomyocytes. PLoS One 12: e0168435. [Crossref]

12.  Szperl M, Kozicka U, Kosiec A, Kukla P, Roszczynko M et al. (2018) Identification novel LQT syndrome-associated variants in Polish population and genotype-phenotype correlations in eight families. J Appl Genet 59: 463-469. [Crossref]

13. Hohneck A, El Battrawy I, Lang S, Ansari U, Schramm K et al. (2019) Protective effect of acquired long QT syndrome in Takotsubo syndrome. Intern Med J 49: 770-776. [Crossref]